首页> 外文期刊>Trends in pharmacological sciences >Targeting of TAK1 in inflammatory disorders and cancer
【24h】

Targeting of TAK1 in inflammatory disorders and cancer

机译:TAK1在炎症性疾病和癌症中的靶向

获取原文
获取原文并翻译 | 示例
           

摘要

The transcription factors nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) are critical regulators of stress responses, immunity, inflammation and cancer. A large variety of cellular stimuli utilize these signaling pathways through a common upstream kinase transforming growth factor-β-activated kinase 1 (TAK1). TAK1 was originally identified as a mitogen-activated kinase kinase kinase (MAP3K) activated by transforming growth factor-β (TGF-β); however, it has been characterized as a key regulator in inflammatory and immune signaling pathways. In addition, microbial proteins and components of host cell signaling scramble for the TAK1 complex in innate immunity. This review highlights the recent advances in the activation mechanisms and physiological functions of TAK1. Research targeting TAK1 raises the potential for new therapeutic options for inflammatory disorders, including cancer.
机译:转录因子核因子-κB(NF-κB)和活化蛋白-1(AP-1)是应激反应,免疫,炎症和癌症的关键调节剂。各种各样的细胞刺激通过共同的上游激酶转化生长因子-β-活化的激酶1(TAK1)利用这些信号传导途径。 TAK1最初被鉴定为通过转化生长因子-β(TGF-β)激活的有丝分裂原激活的激酶激酶(MAP3K);然而,它已被表征为炎症和免疫信号通路中的关键调节剂。此外,微生物蛋白和宿主细胞信号转导的成分在先天免疫中扰乱了TAK1复合物。这篇综述突出了TAK1的激活机制和生理功能的最新进展。针对TAK1的研究提高了针对包括癌症在内的炎症性疾病的新治疗选择的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号